Global X Cybersecurity vs Inovio Pharmaceuticals Inc — how do they compare? Global X Cybersecurity trades at $42.4, while Inovio Pharmaceuticals Inc trades at $1.19 (market cap $95.85M). The key difference: Global X Cybersecurity is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| BUG | INO | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $41.99 | $2.87 |
52-Week Low | $23.30 | $1.05 |
Market Cap | — | $95.85M |
Enterprise Value | — | $66.86M |
Signals from Pluang's Aura AI — not financial advice
BUG trades at $39.64, up 0.69% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock faces resistance near $40 and support at $39. Recent news highlights strong cybersecurity sector tailwinds, with global spending exceeding $300 billion in 2026, though the ETF faces competition from semiconductor-focused alternatives.
Outlook remains positive given cybersecurity's essential role in AI-driven cloud expansion, but valuation premiums and sector competition pose risks. The stock's performance hinges on continued enterprise budget growth and its ability to maintain relevance against disruptive AI technologies.
INO trades at $1.16, down 1.69% on the day, with a bearish technical outlook from moving averages. The company shows minimal revenue of $65.34K in 2025 and a net loss of $84.95M, resulting in a negative net margin of 130,000%. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, alongside shareholder litigation concerns.
The investment case hinges on the binary FDA decision for INO-3107, offering high upside potential but significant risk. Analyst consensus is moderately positive with 53% buy ratings, yet fundamental weaknesses and negative cash flows pose substantial risks for stockholders.
Trailing returns across standard periods
Latest headlines on both assets
BUG is a thematic ETF that invests in companies at the forefront of the global cybersecurity industry. It provides concentrated exposure to leaders in network security, endpoint protection, and cloud security, such as Fortinet, Akamai, and CrowdStrike.
Read more on BUG →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →